Navigation Links
Dr. Magnus Persson Joins Cerecor's Board of Directors

BALTIMORE, Aug. 28, 2012 /PRNewswire/ -- Cerecor Inc. announced today that Magnus Persson, MD Ph.D. has joined the company's Board of Directors. Dr. Persson was one of the original team members at Healthcap, one of the largest biotechnology venture capital firms in Europe.  He became Partner before the first fund was raised in 1996, participated in raising in excess of US$ 1B in international institutional investments and was responsible for deal sourcing, screening and the monitoring of investments as Board representative. He invested in 85 Companies of which 24 have made successful IPO's in various European exchanges and on NASDAQ. Dr. Persson trained at the Karolinska Institute in Stockholm and prior to Healthcap led Phase II and III clinical programs in the Pharmaceutical Industry.

(Logo: )

Magnus currently serves on the Board of Directors of AscendxSpine (private), ConcitPharma (private), Sjalbadan (private) and the Swedish Center for Medical Nanotechnology at Karolinska Institute.  He has previously served on the Boards of Chemocentryx (public), Arpida (public), Tripep (public), PTC Therapeutics (private), Alba Therapeutics (private), Trigen (private), Apoxis (private), SpineVision (private), Carmot Therapeutics (private), MIPS Technology (private), LICA Pharmaceuticals (private), IDEA (private), Neoventa (private) and Prolifix (public).

"Magnus has a vast network within international biopharmaceutical financing communities and has a track record of delivering value for shareholders and stakeholders while expanding the potential of those people who report to him," said Blake Paterson, M.D., the CEO of Cerecor.   Dr. Persson added, "I am delighted to join the Board of Directors of Cerecor and to assist its outstanding management in building a novel and truly differentiated neuroscience Company."

In addition to Drs. Persson and Paterson, Cerecor's Board is Chaired by Dr. Sol Barer and further comprised of members Dr. Gene Bauer and Mssrs. Isaac Blech, John Catsimatidis, and Cary Sucoff.

About Cerecor:  Cerecor Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. We are a Delaware corporation, based in Baltimore and organized in April 2011 in partnership with various laboratories at Johns Hopkins Medical Institute. Cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the mission of commercializing therapeutics that make a difference.

Contact:  John Dierkes, Kennedy Advisors, +1-410-522-8707

SOURCE Cerecor Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Joseph Rogers Joins SRI International as Executive Director of New Health Sciences Section in Biosciences Division
2. Pharmacy Industry Veteran Joins Millennium Pharmacy Systems as SVP Operations
3. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
4. Dr. Gerald Yakatan Joins Imprimis Pharmaceuticals Science and Regulatory Advisory Board
5. MinuteClinic Joins with American Heart Association to Help Americans Reduce High Blood Pressure
6. Stephen G. Austin, CPA Joins Imprimis Pharmaceuticals Board Of Directors
7. Remedy Informatics Joins LongView International Technology Solutions Team to Win CIO-SP3 Contract Award
8. Tara Dall, MD Joins Health Diagnostic Laboratory (HDL, Inc.) as Chief Medical Officer
9. Double Helix Joins McCann Health
10. Prairie Education & Research Cooperative Joins MedNet Solutions iMedNet CRO Partner Program
11. Don Hubbard Joins Checkpoint Surgical As VP Of Sales And Marketing
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Cell Surface Marker Testing ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Safe storage ... creativity of two inventors, one from Lakewood, New Jersey and the other from Bradley ... the patent-pending PROTECTOR to save the expense of having to replace NuvaRings more often ...
(Date:11/28/2015)... ... ... a.m. EST until 11:59 p.m. EST, customers will be racing the clock ... $80 or more to free gifts with purchases, there will be a new sale available ... for skin care and cosmetic needs, customers will save on already discounted prices. , Top ...
(Date:11/27/2015)... ... ... There is only one major question facing all law firms in the ... has not been an easy question to answer. Especially when the senior partners and ... don’t share the same discipline around working long hours. , In addition to ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... University of Toronto and the University of British Columbia suggested that laws requiring bicyclists ... The article explains that part of the reason for the controversial conclusion is that, ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at which ... age, more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions ... overworked. The forgotten part of this equation: 80 percent of medical care occurs ...
Breaking Medicine News(10 mins):